These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19707594)

  • 21. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
    Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
    Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.
    Gallinaro L; Cattini MG; Sztukowska M; Padrini R; Sartorello F; Pontara E; Bertomoro A; Daidone V; Pagnan A; Casonato A
    Blood; 2008 Apr; 111(7):3540-5. PubMed ID: 18245665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.
    O'Donnell J; Laffan MA
    Transfus Med; 2001 Aug; 11(4):343-51. PubMed ID: 11532189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
    Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
    Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
    Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
    Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.
    Fijnvandraat K; Peters M; ten Cate JW
    Br J Haematol; 1995 Oct; 91(2):474-6. PubMed ID: 8547097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
    Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
    Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
    Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW; Montgomery RR; Pratt KP; Lenting PJ; Lillicrap D
    Blood; 2016 Oct; 128(16):2007-2016. PubMed ID: 27587878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
    Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
    Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
    Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
    Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A.
    Ay C; Kovacevic KD; Kraemmer D; Schoergenhofer C; Gelbenegger G; Firbas C; Quehenberger P; Jilma-Stohlawetz P; Gilbert JC; Zhu S; Beliveau M; Koenig F; Iorio A; Jilma B; Derhaschnig U; Pabinger I
    Blood; 2023 Mar; 141(10):1147-1158. PubMed ID: 36108308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.